Its little wonder that when British Home Secretary Jacqui Smith announced to the world that cannabis user figures were in a gentle but perceptible rise, she knew exactly what she was talking about, and was absolutely sure of her facts.
Apparently, offender numbers have shown a marked rise over the last four years even though according [...]
Drug maker Cephalon won’t let Provigil go gently into that post-patent night.
Already, the drugmaker has readied its follow-up: Nuvigil, an extended release form of the stay-awake drug.
Like Effexor and Effexor XR before it (and Wellbutrin and Wellbutrin SR and Wellbutrin XL, and any number of other follow-up twin/triplets), Nuvigil is designed to capture market share [...]
Shares of Cephalon surged Tuesday after the company said its drug Nuvigil met key study goals in a clinical trial involving adults with bipolar disorder.
The stock jumped $4.14, or 6.6 percent, to $67.38 in midday trading. Shares have traded between $58.96 and $81.35 over the last 52 weeks.
Early Tuesday, the company reported that patients taking [...]